摘要
目的探讨不同剂量阿法骨化醇对IgA肾病患者血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)及转化生长因子-β1(TGF-β1)水平的影响。方法选取辽阳市中心医院新城医院2017年1月至2020年1月收治的72例IgA肾病患者作为IgA肾病组,另选择同时期于辽阳市中心医院新城医院健康体检人员65例作为对照组,采取随机数字表法将IgA肾病患者分为小剂量组与大剂量组,每组36例。小剂量组给予0.25μg阿法骨化醇胶丸,大剂量组给予0.5μg阿法骨化醇胶丸,比较IgA肾病组及对照组、小剂量组与大剂量组治疗前后血清TNF-α、IL-6及TGF-β1水平。结果治疗前,Ig A肾病组血清TNF-α、IL-6及TGF-β1水平高于对照组,差异有统计学意义(P<0.05)。治疗后,小剂量组与大剂量组血清TNF-α、IL-6及TGF-β1水平降低,且大剂量组上述指标降低更加显著,差异有统计学意义(P<0.05)。结论IgA肾病患者中存在着明显的炎症反应,大剂量相比于小剂量阿法骨化醇治疗IgA肾病患者可明显改善血清TNF-α、IL-6及TGF-β1水平。
Objective To investigate and analyze the effects of different doses of alfacalcitol on serum TNF-α,IL-6 and TGF-β1 in patients with IgA nephropathy.Methods A total of 72 patients with IgA nephropathy admitted to Liaoyang Zhongxin Xincheng Hospital from January 2017 to January 2020 were selected as IgA nephropathy group,and 65 healthy persons who were having physical examination in the hospital were selected as the control group.Patients with IgA nephropathy were assigned into low dose group and high dose group,with 36 cases in each group according to random number table.The low dose group was given 0.25 ug alfacalcidol capsule,and the high dose group was given 0.5 ug alfacalcidol capsule.The serum levels of TNF-α,IL-6 and TGF-β1 in IgA nephropathy group,control group,low-dose group and high-dose group were compared before and after treatment.Results Before therapy,the serum levels of TNF-α,IL-6 and TGF-β1 in the IgA nephropathy group were higher than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the serum levels of TNF-α,IL-6 and TGF-β1 in the low dose and high dose groups were all decreased,and the reduction of the above indicators was more significant in the high-dose group than in the low-dose group,with statistically significant difference(P<0.05).Conclusion There is a significant inflammatory response in patients with IgA nephropathy.The serum TNF-α,IL-6 and TGF-β1 levels in IgA renal patients were significantly improved with high dose of alfacalicol compared with low dose.
作者
张晓楠
ZHANG Xiao-Nan(Department of Dialysis,Liaoyang Zhongxin Xincheng Hospital,Liaoyang 111000,China)
出处
《中国药物经济学》
2020年第12期103-105,109,共4页
China Journal of Pharmaceutical Economics
